ADAP Advocacy launches survey about long-acting injectable treatment

An online survey launched by ADAP Advocacy is looking for people living with HIV in the U.S. to share their thoughts about long-acting injectable (LAI) medications.

LAIs are administered by injection and can work for months to prevent or to treat HIV. While intended as an alternative to daily oral pills, access to this new type of treatment has faced challenges in some cases.

“Obstacles and operational barriers to timely access of new agents, especially injectables, have increased with the advent of newer injectable therapies” said Riley Johnson, project manager of ADAP Advocacy’s LAI project. “The barriers that commonly occur hinder equitable access for people living with HIV, especially those relying on publicly financed programs such as state AIDS Drug Assistance Programs or Medicaid, but also for people on private insurance. Our survey provides patients an opportunity to share their experiences.”

At present, the U.S. Food and Drug Administration has approved one drug—cabotegravir (marketed under the brand name Apretude)—for HIV prevention, and two LAIs for HIV treatment—a combination of cabotegravir with rilpivirine that is a complete regimen (brand name Cabenuva)—and lenacapavir (Sunlenca), a drug that must still be taken with oral medications.

ADAP Advocacy is a nonprofit that works with community, healthcare, government, policy, pharmaceutical companies and other stakeholders to improve access to care for people living with HIV.

Individuals living with HIV in the U.S. can take the confidential survey at

For more information, email